Casdin Capital LLC purchased a new stake in shares of Exscientia plc (NASDAQ:EXAI – Get Rating) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 713,900 shares of the company’s stock, valued at approximately $14,107,000. Casdin Capital LLC owned 0.61% of Exscientia at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of the business. Novo Holdings A S purchased a new position in shares of Exscientia during the 4th quarter worth approximately $258,591,000. Bill & Melinda Gates Foundation bought a new stake in shares of Exscientia in the 4th quarter worth approximately $31,400,000. Pictet Asset Management SA bought a new stake in shares of Exscientia in the 4th quarter worth approximately $31,402,000. Mitsubishi UFJ Trust & Banking Corp bought a new position in Exscientia in the 4th quarter valued at approximately $4,200,000. Finally, Border to Coast Pensions Partnership Ltd bought a new position in Exscientia in the 4th quarter valued at approximately $2,590,413,000. Hedge funds and other institutional investors own 37.09% of the company’s stock.
Several equities analysts have recently weighed in on the company. Zacks Investment Research raised Exscientia from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Wednesday, April 13th. Morgan Stanley raised their price objective on shares of Exscientia from $20.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Monday, April 11th. Finally, The Goldman Sachs Group reduced their target price on shares of Exscientia from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday.
Exscientia (NASDAQ:EXAI – Get Rating) last released its quarterly earnings data on Wednesday, May 25th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). Research analysts forecast that Exscientia plc will post -0.42 earnings per share for the current year.
Exscientia Profile (Get Rating)
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection.
- Get a free copy of the StockNews.com research report on Exscientia (EXAI)
- Genesco Pops On Earnings But Don’t Expect A Rally
- The Insiders Are Selling Movado Group, But You Shouldn’t
- Beware The Rebound In Retail Stocks
- It’s A Good Time To Own Ralph Lauren (NYSE: RL)
- Block, Inc: Correcting for Negative Earnings
Receive News & Ratings for Exscientia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exscientia and related companies with MarketBeat.com's FREE daily email newsletter.